{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:15Z","timestamp":1789628475995,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030833","name":"Syneos Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.rpth.2025.103201","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:56:37Z","timestamp":1759798597000},"page":"103201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Andexanet alfa vs standard of care for factor Xa inhibitor-induced intracranial hemorrhage\u2014a systematic review and meta-analysis"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-1319","authenticated-orcid":false,"given":"Alexander J.","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Lopes","family":"Sadafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Principato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrad","family":"Nowrouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Eshaghpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103201_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1472-8206.2011.00981.x","article-title":"Pharmacodynamic and pharmacokinetic basics of rivaroxaban","volume":"26","author":"Kreutz","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.rpth.2025.103201_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13318-011-0037-x","article-title":"Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor","volume":"36","author":"He","year":"2011","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.rpth.2025.103201_bib3","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103201_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rpth.2025.103201_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103201_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.17925\/HI.2020.14.1.20","article-title":"Andexanet alfa and its clinical application","volume":"14","author":"Noordergraaf","year":"2020","journal-title":"Heart Int"},{"key":"10.1016\/j.rpth.2025.103201_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","article-title":"Direct oral anticoagulants: a quick guide","volume":"12","author":"Julia","year":"2017","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.rpth.2025.103201_bib8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103201_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/bloodadvances.2020003560","article-title":"Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry","volume":"5","author":"Bassand","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103201_bib10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5830\/CVJA-2021-060","article-title":"Bleeding complications in patients on new oral anticoagulants for venous thromboembolism in Kenya","volume":"33","author":"Obayo","year":"2022","journal-title":"Cardiovasc J Afr"},{"key":"10.1016\/j.rpth.2025.103201_bib11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.5694\/j.1326-5377.2004.tb06407.x","article-title":"Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis","volume":"181","author":"Baker","year":"2004","journal-title":"Med J Aust"},{"key":"10.1016\/j.rpth.2025.103201_bib12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/asheducation-2016.1.612","article-title":"Reversal of direct oral anticoagulants: a practical approach","volume":"2016","author":"Shih","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2025.103201_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/0885066619882909","article-title":"Four-factor prothrombin complex concentrate for the reversal of direct oral anticoagulants","volume":"36","author":"Zada","year":"2021","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.rpth.2025.103201_bib14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1017\/S0265021508004675","article-title":"Prothrombin complex concentrates: a brief review","volume":"25","author":"Samama","year":"2008","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.rpth.2025.103201_bib15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.5811\/westjem.2019.4.41649","article-title":"Thromboembolic risk of 4-factor prothrombin complex concentrate versus fresh frozen plasma for urgent warfarin reversal in the emergency department","volume":"20","author":"Maguire","year":"2019","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.rpth.2025.103201_bib16","series-title":"StatPearls. Treasure Island, FL","article-title":"Andexanet alfa","author":"Reed","year":"2024"},{"key":"10.1016\/j.rpth.2025.103201_bib17","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103201_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13054-022-04043-8","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis","volume":"26","author":"Costa","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.rpth.2025.103201_bib19","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103201_bib20","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103201_bib21","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103201_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11239-019-01846-5","article-title":"Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study","volume":"48","author":"Smith","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2025.103201_bib23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0885066619840992","article-title":"A low-dose 4F-PCC protocol for DOAC-associated intracranial hemorrhage","volume":"35","author":"Berger","year":"2020","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.rpth.2025.103201_bib24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2025.103201_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.rpth.2025.103201_bib26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE reporting guidelines for meta-analyses of observational studies","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.rpth.2025.103201_bib27","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2025.103201_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2025.103201_bib29","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2019"},{"key":"10.1016\/j.rpth.2025.103201_bib30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2025.103201_bib31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/17474930241230209","article-title":"Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - individual patient data analysis of ANNEXA-4 and TICH-NOAC","volume":"19","author":"Siepen","year":"2024","journal-title":"Int J Stroke"},{"key":"10.1016\/j.rpth.2025.103201_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MBC.0000000000001279","article-title":"The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage","volume":"35","author":"Irizarry-Gatell","year":"2024","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2025.103201_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.japh.2023.11.015","article-title":"Four-factor prothrombin complex concentrate versus Andexanet alfa for direct oral anticoagulant reversal","volume":"64","author":"Koo","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.rpth.2025.103201_bib34","doi-asserted-by":"crossref","first-page":"939","DOI":"10.5811\/WESTJEM.60587","article-title":"Treatment of factor-Xa inhibitor-associated bleeding with andexanet alfa or 4 factor PCC: a multicenter feasibility retrospective study","volume":"24","author":"Singer","year":"2023","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.rpth.2025.103201_bib35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11239-023-02840-8","article-title":"Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds","volume":"56","author":"Keinath","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2025.103201_bib36","article-title":"Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study","volume":"7","author":"Dobesh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103201_bib37","article-title":"Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding","volume":"3","author":"Cohen","year":"2022","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"10.1016\/j.rpth.2025.103201_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11239-022-02752-z","article-title":"Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage","volume":"55","author":"Lipski","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2025.103201_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ajem.2022.11.023","article-title":"The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage","volume":"64","author":"Oh","year":"2023","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.rpth.2025.103201_bib40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11239-022-02715-4","article-title":"Retrospective review of andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of DOAC-associated intracranial hemorrhage","volume":"55","author":"Troyer","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2025.103201_bib41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ajem.2022.02.036","article-title":"Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: a single-center, retrospective, matched cohort analysis","volume":"55","author":"Parsels","year":"2022","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.rpth.2025.103201_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MBC.0000000000001128","article-title":"Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre","volume":"33","author":"Milioglou","year":"2022","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2025.103201_bib43","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/STROKEAHA.121.034572","article-title":"Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor\u2013related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care","volume":"53","author":"Huttner","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2025.103201_bib44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11239-021-02495-3","article-title":"Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage","volume":"53","author":"Vestal","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2025.103201_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211039020","article-title":"Retrospective comparison of andexanet alfa and 4-factor prothrombin complex for reversal of factor Xa-inhibitor related bleeding","volume":"27","author":"Stevens","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2025.103201_bib46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/fca-2020-0073","article-title":"Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study","volume":"17","author":"Coleman","year":"2021","journal-title":"Future Cardiol"},{"key":"10.1016\/j.rpth.2025.103201_bib47","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/jth.14838","article-title":"Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages","volume":"18","author":"Barra","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103201_bib48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12028-020-01161-5","article-title":"Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage","volume":"35","author":"Ammar","year":"2021","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.rpth.2025.103201_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11239-019-01973-z","article-title":"Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage","volume":"49","author":"Frontera","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2025.103201_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajem.2022.02.029","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages","volume":"55","author":"Pham","year":"2022","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.rpth.2025.103201_bib51","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/10600280241297701","article-title":"Incidence of venous thromboembolism post-oral anticoagulation reversal in intracranial hemorrhage patients","volume":"59","author":"Abdulla","year":"2025","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rpth.2025.103201_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2025.103201_bib53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/phar.2925","article-title":"Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: a systematic review with meta-analysis","volume":"44","author":"White","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rpth.2025.103201_bib54","doi-asserted-by":"crossref","first-page":"e1025","DOI":"10.1097\/CCM.0000000000005059","article-title":"Andexanet alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis","volume":"49","author":"Nederpelt","year":"2021","journal-title":"Crit Care Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:57:21Z","timestamp":1773255441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925005254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2475037925005254"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103201","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Andexanet alfa vs standard of care for factor Xa inhibitor-induced intracranial hemorrhage\u2014a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103201"}}